VONOPRAZAN is a first-in-class PCAB¹

PHARMACODYNAMIC STUDY

MECHANISTIC DIFFERENCES

In a pharmacodynamic study in healthy volunteers,*

Vonoprazan has been shown to provide rapid, potent, and durable acid suppression¹

RAPID

Starts to suppress acid quickly
within 2-3 hours

Icon of a stomach filled with gastric acid

POTENT

Achieves steady state by Day 4,
with a mean pH of 6

DURABLE

Maintains continuous acid
suppression over 24 hours

*Vonoprazan 20 mg QD was evaluated in this study. The approved dose of vonoprazan as part of an H. pylori treatment regimen is 20 mg BID.
BID=twice daily; QD=once daily.

Select mechanistic differences between vonoprazan and lansoprazole^1-3

PRODUCT ATTRIBUTES	VONOPRAZAN	LANSOPRAZOLE
Mean half-life	7.1 hours	1.5 hours
Dosing with food	Can be taken with or without food	Needs to be taken before a meal
Interaction with active acid pumps	Noncovalent and reversible	Covalent and irreversible
The clinical significance of these mechanistic differences has not been established.

Discover the power of VOQUEZNA-based regimens

SEE eradication rates

VONOPRAZAN is a first-in-class PCAB1

Vonoprazan has been shown to provide rapid, potent, and durable acid suppression1

Select mechanistic differences between vonoprazan and lansoprazole1-3

VONOPRAZAN is a first-in-class PCAB¹

Vonoprazan has been shown to provide rapid, potent, and durable acid suppression¹

Select mechanistic differences between vonoprazan and lansoprazole^1-3